Corbus Pharmaceuticals Holdings, Inc. (CRBP)
NASDAQ: CRBP · Real-Time Price · USD
7.42
-0.26 (-3.39%)
Feb 20, 2026, 4:00 PM EST - Market closed
CRBP Employees
Corbus Pharmaceuticals Holdings had 28 employees as of December 31, 2024. The number of employees increased by 9 or 47.37% compared to the previous year.
Employees
28
Change (1Y)
9
Growth (1Y)
47.37%
Revenue / Employee
n/a
Profits / Employee
-$2,411,143
Market Cap
137.48M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 28 | 9 | 47.37% |
| Dec 31, 2023 | 19 | -14 | -42.42% |
| Dec 31, 2022 | 33 | -8 | -19.51% |
| Dec 31, 2021 | 41 | -35 | -46.05% |
| Dec 31, 2020 | 76 | -65 | -46.10% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sangamo Therapeutics | 183 |
| Vaxart | 105 |
| Tenaya Therapeutics | 97 |
| Spero Therapeutics | 32 |
| Black Diamond Therapeutics | 24 |
| Unicycive Therapeutics | 23 |
| Whitehawk Therapeutics | 22 |
| ProMIS Neurosciences | 8 |
CRBP News
- 9 days ago - Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference - GlobeNewsWire
- 5 weeks ago - Corbus Pharmaceuticals Holdings, Inc. (CRBP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 6 weeks ago - Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Phase 1a Single-Ascending and Multiple-Ascending Dose Data Transcript - Seeking Alpha
- 2 months ago - Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss - GlobeNewsWire
- 2 months ago - Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025 - GlobeNewsWire
- 3 months ago - Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Corbus Pharmaceuticals: Data Update And Fundraising Efforts Do Not Diminish The Thesis - Seeking Alpha